Abstract:Proximal tubule (PT) dysfunction, including tubular proteinuria, is a significant complication in sickle cell disease (SCD) that can eventually lead to chronic kidney disease. The PT is especially susceptible to cytotoxic damage, and tubular dysfunction in SCD is thought to result from prolonged exposure to hemoglobin (Hb) released from damaged red blood cells. Filtered Hb dimers are internalized into PT cells upon binding to the multiligand receptors megalin and cubilin. These receptors bind to numerous filtered proteins, including albumin and vitamin D binding protein, and are important for maintaining protein‐free urine and vitamin D homeostasis. We hypothesized that toxicity from exposure to Hb could impair PT cell endocytic function, causing tubular proteinuria. Using a fluorescence‐based protein uptake assay in a PT cell culture model, we found that concentrations of Hb predicted to enter the tubule lumen during hemolytic crisis profoundly inhibit the uptake of other megalin/cubilin ligands (albumin and vitamin D binding protein) by PT cells. These effects were independent of heme reduction state, occurred in the absence of a cytotoxic response, and appear to be due to direct competition for megalin/cubilin binding. The Glu7Val mutant that causes SCD was equally effective at inhibiting albumin uptake compared with wild type Hb. Haptoglobin restored albumin uptake in the presence of Hb, suggesting that haptoglobin binding to the Hb αβ dimer‐dimer interface interferes with Hb binding to megalin/cubilin. Using these data, we established a robust, scalable assay that enables us to screen for selective inhibitors of Hb uptake that preserve PT function. Our studies suggest that the primary cause of tubular proteinuria in SCD is impaired endocytosis of megalin/cubilin ligands due to competition from filtered Hb, rather than toxicity. Our data also suggest a potential explanation for the vitamin D deficiency commonly observed in sickle cell patients. Current studies are focused on characterizing the effects of Hb on vitamin D metabolism and signaling in PT cells. Support or Funding Information National Institutes of Health RO1 DK101484, RO1 DK100357, P30 DK079307, T32 DK061296, TL1 TR001858; Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute P3HVB pilot grant This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .

Sickle Hemoglobinopathy and the Kidney1

Hemoglobin Inhibits Uptake of Filtered Proteins by Proximal Tubule Cells: Implications for Sickle Cell Disease and Vitamin D Status

Potassium dynamics in sickle cell anemia: clinical implications and pathophysiological insights

Vascular pathophysiology of sickle cell disease

[Hemostasis alterations in sickle cell syndrome]

Heme induced loss of renovascular endothelial protein C receptor promotes chronic kidney disease in sickle mice

Nontargeted Plasma Proteomic Analysis of Renal Disease and Pulmonary Hypertension in Patients with Sickle Cell Disease

Management of Acute Complications of Sickle Cell Disease

Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications

Sickle cell disease as a vascular disorder

Chronic organ failure in adult sickle cell disease

Vasculopathy in Sickle Cell Disease: From Red Blood Cell Sickling to Vascular Dysfunction

Random Occurrence or Real Association? Primary Hyperparathyroidism in a Young Man With Sickle Cell Disease

End Organ Affection in Sickle Cell Disease

Curative Therapies for Sickle Cell Disease

Hypercoagulability in Sickle Cell Disease: A Thrombo-Inflammatory Mechanism

Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients, as a function of therapeutic transfusion and hydroxyurea treatment

Disease-Modifying Therapies for Sickle Cell Disease—An Overview

Heme- and iron-activated macrophages in sickle cell disease: an updated perspective

Systematic Review of Genetic Modifiers Associated with the Development and/or Progression of Nephropathy in Patients with Sickle Cell Disease

Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment